Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[$pepgs](/topic/$pepgs)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"Down-to-earth data-based discussion of $pepg's DM1 program safety and efficacy. $dyn $rna"  
[X Link](https://x.com/RNAiAnalyst/status/1978588482315378977) [@RNAiAnalyst](/creator/x/RNAiAnalyst) 2025-10-15T22:27Z 20.5K followers, 8623 engagements


"I have seen a number of posts questioning the safety of $PEPG's DM1 therapy based on previously published results for $PEPG's DMD therapy. I think there are a few misunderstandings regarding safety that are important to clear up. For background $PEG 's EDO-DM1 treats Myotonic Dystrophy Type X. EDO-51 treated DMD XX. These are two very different genetic diseases and both the structure and functional objective of each therapy's ASO is correspondingly very different. First $PEPG's EDO-51 DMD program was terminated by PEPGEN for efficacy not for safety. The mean increase in dystrophin expression"  
[X Link](https://x.com/medstudentinvst/status/1973020486834507891) [@medstudentinvst](/creator/x/medstudentinvst) 2025-09-30T13:41Z XXX followers, 3633 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$pepgs

Top Social Posts

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"Down-to-earth data-based discussion of $pepg's DM1 program safety and efficacy. $dyn $rna"
X Link @RNAiAnalyst 2025-10-15T22:27Z 20.5K followers, 8623 engagements

"I have seen a number of posts questioning the safety of $PEPG's DM1 therapy based on previously published results for $PEPG's DMD therapy. I think there are a few misunderstandings regarding safety that are important to clear up. For background $PEG 's EDO-DM1 treats Myotonic Dystrophy Type X. EDO-51 treated DMD XX. These are two very different genetic diseases and both the structure and functional objective of each therapy's ASO is correspondingly very different. First $PEPG's EDO-51 DMD program was terminated by PEPGEN for efficacy not for safety. The mean increase in dystrophin expression"
X Link @medstudentinvst 2025-09-30T13:41Z XXX followers, 3633 engagements

$pepgs
/topic/$pepgs/posts